Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Clinical Trial to Evaluate the Safety, Efficacy, and Cellular Kinetics of CT0596 CAR-T Cell Injection in Patients With Relapsed/Refractory Multiple Myeloma

NCT07760454 is registered in ClinicalTrials.gov with UCARsgen Biotech Limited as lead sponsor.

NCT NCT07760454
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07760454 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Clinical Trial to Evaluate the Safety, Efficacy, and Cellular Kinetics of CT0596 CAR-T Cell Injection in Patients With Relapsed/Refractory Multiple Myeloma
Lead sponsor
UCARsgen Biotech Limited
Phase
Phase 1/2
Overall status
Recruiting
Start date
September 3, 2026
Completion date
April 30, 2031
Enrollment
68 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed/refractory multiple myeloma